Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound drug capable of resisting prostatic cancer

An anti-prostate cancer and drug technology, used in drug combinations, anti-tumor drugs, pharmaceutical formulations, etc., can solve problems such as insignificant effects, and achieve the effects of reducing toxic side effects, low doses, and lower concentrations

Active Publication Date: 2019-10-15
WUYI UNIV
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, traditional Chinese medicine adopts formulas composed of haptophylla, motherwort, coptis, kelp, fennel, maple bark, lychee core, commelina, yarrow and other Chinese medicinal materials for treatment, but the effect is not obvious.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound drug capable of resisting prostatic cancer
  • Compound drug capable of resisting prostatic cancer
  • Compound drug capable of resisting prostatic cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] A compound anti-prostate cancer drug, the drug is composed of nobiletin and bicalutamide. By applying the drugs described in this example to androgen-independent prostate cancer PC-3 cells, carry out MTT assay to measure cell activity; For prostate cancer PC-3 cells, MTT assay was performed to measure the cell viability as a comparison. Methods as below:

[0025] Prostate cancer PC-3 cells at a density of 0.4×10 5 100 μL of cells / ml was placed in a 96-well plate, placed in a 37°C, 5% incubator and cultured for 24 hours, then treated with different concentrations of nobiletin and bicalutamide for 72 hours, and added 0.5 mg / ml of MTT into the Incubate in an incubator for 4 hours, add 100 μL of DMSO and incubate for 10 minutes, then measure the absorbance at a wavelength of 490 nm.

[0026] Wherein, the concentrations of nobiletin are 20 μM, 30 μM, 40 μM, and 50 μM respectively, and the concentrations of bicalutamide are 20 μM, 30 μM, 40 μM, and 50 μM respectively, and ...

Embodiment 2

[0028] A compound anti-prostate cancer drug, the drug is composed of nobiletin and bicalutamide, by the drug described in this embodiment acting on androgen-dependent prostate cancer VCaP cells, and carrying out MTT assay to measure cell activity; Simultaneously, nobiletin and bicalutamide were used alone to act on androgen-dependent prostate cancer VCaP cells, and the MTT test was carried out to measure the cell activity as a comparison; the method was the same as in Example 1, wherein the concentrations of each drug were:

[0029] The concentration of nobiletin is 20 μM, 30 μM, 40 μM, 50 μM, the concentration of bicalutamide is 20 μM, 30 μM, 40 μM, 50 μM, and the combined administration concentration is (nobiletin + bicalutamide) 20 μM+20 μM, 30 μM+ 30μM, 40μM+40μM, 50μM+50μM. The result is as figure 2 shown, from figure 2 It can be seen that the survival rate of VCaP cells in the single drug group and the combined drug group increased with the increase of the drug conce...

Embodiment 3

[0031] A compound anti-prostate cancer drug, the drug is composed of nobiletin and bicalutamide. Through the experimental analysis of the combination drug of this example inducing the apoptosis of androgen-independent prostate cancer cell PC-3 cells, at the same time, nobiletin and bicalutamide were administered alone to induce androgen-independent prostate cancer cell PC-3 -3 Experimental analysis of cell apoptosis, as a comparison.

[0032] The method is as follows: Prostate cancer cell PC-3 was treated at a density of 0.2×10 5 cells / ml was added to a 35mm petri dish, incubated in an incubator for 24 hours and after the cells adhered to the wall, nobiletin and bicalutamide were administered alone or in combination for 72 hours. Draw the old culture base into a centrifuge tube, wash once with 300μl PBS, add 200μl trypsin to digest, add 600μl complete medium to stop digestion, then wash again with 800μl, centrifuge at 1200r / min for 5min, absorb the upper medium, add 500μl PBS...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a compound drug capable of resisting the prostatic cancer. The compound drug consists of a polymethoxyflavone drug and an androgen receptor inhibitor drug, wherein the mass ratio of the polymethoxyflavone drug to the androgen receptor inhibitor drug is 1:1, the polymethoxyflavone drug is nobiletin, and the androgen receptor inhibitor drug is bicalutamide. The polymethoxyflavone drug and the androgen receptor inhibitor anti-cancer drug are jointly used, a drug function is obviously superior to single drug utilization, and therefore, the compound drug has a good inhibitioneffect on inhibiting the prostatic cancer and preventing the prostatic cancer to develop to malignance. The drug provided by the invention is low in a use dosage, and lowers the concentration of single drug utilization so as to reduce the toxic and side effects of the drug and reduce harm on the human body, the economic burden of a patient is further reduced through mixed utilization, and the compound drug performs a better effect than single utilization.

Description

technical field [0001] The invention relates to the technical field of anticancer drugs, in particular to a compound anti-prostate cancer drug. Background technique [0002] Cancer is a malignant disease that seriously threatens human health and is one of the main "killers" of human death. Prostate cancer is a malignant tumor that occurs in male prostate tissue, and its mortality rate ranks second among male cancer patients, second only to lung cancer. [0003] Prostate cancer refers to epithelial malignant tumors that occur in the prostate. According to the 2004 WHO "Pathology and Genetics of Tumors of the Urinary System and Male Reproductive Organs", the pathological types of prostate cancer include adenocarcinoma (acinar adenocarcinoma), ductal adenocarcinoma, urothelial carcinoma, squamous cell carcinoma, and adenosquamous carcinoma. . Among them, prostate adenocarcinoma accounts for more than 95%. Therefore, what we usually call prostate cancer refers to prostate ade...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/352A61K31/277A61P35/00
CPCA61K45/06A61K31/352A61K31/277A61P35/00A61K2300/00
Inventor 马于然郑希李冬利任想张焜刘文峰徐学涛盛昭君
Owner WUYI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com